Atara Biopharmaceuticals (ATRA) Shares Off Sharply after PEW Drug Fails Phase 2 Study

Shares of Atara Biopharmaceuticals Inc. (ATRA) were trading down -13.20 or -39.76 percent to $20.00 per share in this morning's premarket after the company announced early this morning that its product candidate for the treatment of protein energy wasting or PEW had failed a Phase 2 clinical trial. Atara Bio stock closed at $33.20 per ... READ MORE Read the rest of Atara Biopharmaceuticals (ATRA) Shares Off Sharply after PEW Drug Fails Phase 2 Study at InvestorGuide.com .